-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to relevant statistics, in January 2022, a total of 28 key pharmaceutical companies in the new drug field completed investments, with a total financing amount exceeding 5 billion yuan
.
Judging from the focus areas of these financing pharmaceutical companies, they mainly focus on immune cell therapy, CAR-T cell therapy, and tumor drugs
.
The industry pointed out that the underlying logic of investment in the new drug field still lies in the continuous satisfaction of clinical needs, such as the tumor field, which are all barriers that the new drug field is eager to break through
.
Entering February, news of oncology drug companies receiving large amounts of financing continued to come
.
For example, on February 8, Yossen Jianheng announced that it had recently completed more than 200 million yuan in Series A financing
.
This round of financing was led by Shenzhen Sharing Investment, followed by Zhang Jiang Haoheng and Yingke Capital.
The original shareholders continued to participate in this round of investment
.
It is reported that the funds raised in this round will be used to carry out and accelerate the global clinical trials of UA007 and UA021, the development of small molecule drugs for multiple new targets, and the development of specific double-antibody drugs
.
Eusen Jianheng has established a relatively complete R&D team with complementary expertise and resources, focusing on the new generation of tumors and autoimmune fields, and has broad market development prospects
.
On February 14, another pharmaceutical company announced the completion of hundreds of millions of financing
.
Qinhao Pharmaceutical (Suzhou) Co.
, Ltd.
(hereinafter referred to as "Qinhao Pharmaceutical") announced that the company has completed a series B financing of several hundred million yuan
.
This round of financing was led by Linkage Ventures, followed by Gandao Fund, Panyi Investment, Guohai Innovation Capital and other institutions.
The old shareholder, Legend Star, continued to make additional investment
.
According to the data, Qinhao Pharmaceutical is a global innovative biopharmaceutical company, focusing on the development of original anti-tumor small molecule new drugs
.
At present, the company has built and improved four new drug research and development centers, namely the innovation research center, the drug design and discovery center, the new drug screening and evaluation center, and the clinical development center, and has built a product research and development pipeline with more than 10 projects. .
In March 2021, the IND application of Qinhao Pharmaceutical's GH35 product (KRAS inhibitor) was accepted by the CDE; in the same year, the SHP2 project GH21 received clinical approvals from both China and the United States.
In charge, the first patient dosing has been completed in January 2022
.
With the company's two products entering the clinic, Qinhao's development will also enter a new stage
.
Qinhao continues to develop the RAS signaling pathway, and around this pathway, several projects including SOS1 inhibitor and pan-KRAS inhibitor are in rapid progress
.
At the same time, the pipeline 2.
0, which is more innovative, competitive and global value, is also expected to achieve breakthroughs
.
According to the managing partner of Linkage Ventures, the Qinhao Pharmaceutical team has been working on the development, demonstration and molecular optimization of new targets for many years, and the development potential is promising
.
However, in recent years, the development of small-molecule drugs is also limited by the fact that the growth rate of new target discovery and the diversity of small-molecule libraries is decreasing year by year, which makes the development of small-molecule drugs at a relatively low success rate
.
However, the development and progress of new technologies such as PROTAC technology, molecular glue, and AI drug research and development have brought new research and development ideas to the research and development of small-molecule drugs, and the research and development of small-molecule drugs has been revived
.
It is reported that this round of financing will be used by the company to increase investment in research and development, improve and upgrade its internal research and development platform, enrich product pipelines and accumulate core technologies by continuously introducing high-level talents
.
Previously, Qinhao Pharma has also completed multiple rounds of financing
.
For example, in June 2021, Qinhao Pharma announced the completion of a Series A financing of over 200 million yuan
.
This round of financing was led by Shenzhen Venture Capital, followed by Via Bio, Yoyin Medical Fund, Lenovo Star and other institutions.
The old shareholder Shengyu Investment continued to make additional investments
.
.
Judging from the focus areas of these financing pharmaceutical companies, they mainly focus on immune cell therapy, CAR-T cell therapy, and tumor drugs
.
The industry pointed out that the underlying logic of investment in the new drug field still lies in the continuous satisfaction of clinical needs, such as the tumor field, which are all barriers that the new drug field is eager to break through
.
Entering February, news of oncology drug companies receiving large amounts of financing continued to come
.
For example, on February 8, Yossen Jianheng announced that it had recently completed more than 200 million yuan in Series A financing
.
This round of financing was led by Shenzhen Sharing Investment, followed by Zhang Jiang Haoheng and Yingke Capital.
The original shareholders continued to participate in this round of investment
.
It is reported that the funds raised in this round will be used to carry out and accelerate the global clinical trials of UA007 and UA021, the development of small molecule drugs for multiple new targets, and the development of specific double-antibody drugs
.
Eusen Jianheng has established a relatively complete R&D team with complementary expertise and resources, focusing on the new generation of tumors and autoimmune fields, and has broad market development prospects
.
On February 14, another pharmaceutical company announced the completion of hundreds of millions of financing
.
Qinhao Pharmaceutical (Suzhou) Co.
, Ltd.
(hereinafter referred to as "Qinhao Pharmaceutical") announced that the company has completed a series B financing of several hundred million yuan
.
This round of financing was led by Linkage Ventures, followed by Gandao Fund, Panyi Investment, Guohai Innovation Capital and other institutions.
The old shareholder, Legend Star, continued to make additional investment
.
According to the data, Qinhao Pharmaceutical is a global innovative biopharmaceutical company, focusing on the development of original anti-tumor small molecule new drugs
.
At present, the company has built and improved four new drug research and development centers, namely the innovation research center, the drug design and discovery center, the new drug screening and evaluation center, and the clinical development center, and has built a product research and development pipeline with more than 10 projects. .
In March 2021, the IND application of Qinhao Pharmaceutical's GH35 product (KRAS inhibitor) was accepted by the CDE; in the same year, the SHP2 project GH21 received clinical approvals from both China and the United States.
In charge, the first patient dosing has been completed in January 2022
.
With the company's two products entering the clinic, Qinhao's development will also enter a new stage
.
Qinhao continues to develop the RAS signaling pathway, and around this pathway, several projects including SOS1 inhibitor and pan-KRAS inhibitor are in rapid progress
.
At the same time, the pipeline 2.
0, which is more innovative, competitive and global value, is also expected to achieve breakthroughs
.
According to the managing partner of Linkage Ventures, the Qinhao Pharmaceutical team has been working on the development, demonstration and molecular optimization of new targets for many years, and the development potential is promising
.
However, in recent years, the development of small-molecule drugs is also limited by the fact that the growth rate of new target discovery and the diversity of small-molecule libraries is decreasing year by year, which makes the development of small-molecule drugs at a relatively low success rate
.
However, the development and progress of new technologies such as PROTAC technology, molecular glue, and AI drug research and development have brought new research and development ideas to the research and development of small-molecule drugs, and the research and development of small-molecule drugs has been revived
.
It is reported that this round of financing will be used by the company to increase investment in research and development, improve and upgrade its internal research and development platform, enrich product pipelines and accumulate core technologies by continuously introducing high-level talents
.
Previously, Qinhao Pharma has also completed multiple rounds of financing
.
For example, in June 2021, Qinhao Pharma announced the completion of a Series A financing of over 200 million yuan
.
This round of financing was led by Shenzhen Venture Capital, followed by Via Bio, Yoyin Medical Fund, Lenovo Star and other institutions.
The old shareholder Shengyu Investment continued to make additional investments
.
